WO2005070924A8 - Substituted quinolines and their use as mycobacterial inhibitors - Google Patents

Substituted quinolines and their use as mycobacterial inhibitors

Info

Publication number
WO2005070924A8
WO2005070924A8 PCT/EP2005/050267 EP2005050267W WO2005070924A8 WO 2005070924 A8 WO2005070924 A8 WO 2005070924A8 EP 2005050267 W EP2005050267 W EP 2005050267W WO 2005070924 A8 WO2005070924 A8 WO 2005070924A8
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
hydrogen
het
alkyloxy
alkylthio
Prior art date
Application number
PCT/EP2005/050267
Other languages
French (fr)
Other versions
WO2005070924A1 (en
Inventor
Jerome Emile George Guillemont
Elisabeth Therese Jea Pasquier
Original Assignee
Janssen Pharmaceutica Nv
Jerome Emile George Guillemont
Elisabeth Therese Jea Pasquier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2006550174A priority Critical patent/JP4773975B2/en
Priority to CN2005800026797A priority patent/CN1910177B/en
Priority to BRPI0507076A priority patent/BRPI0507076B8/en
Priority to US10/596,386 priority patent/US7338949B2/en
Priority to EA200601363A priority patent/EA011359B1/en
Priority to DE602005006101T priority patent/DE602005006101T2/en
Priority to CA2553266A priority patent/CA2553266C/en
Priority to AU2005206330A priority patent/AU2005206330B2/en
Application filed by Janssen Pharmaceutica Nv, Jerome Emile George Guillemont, Elisabeth Therese Jea Pasquier filed Critical Janssen Pharmaceutica Nv
Priority to KR1020067013237A priority patent/KR101150172B1/en
Priority to AP2006003693A priority patent/AP2188A/en
Priority to NZ547277A priority patent/NZ547277A/en
Priority to EP05701586A priority patent/EP1711492B1/en
Publication of WO2005070924A1 publication Critical patent/WO2005070924A1/en
Publication of WO2005070924A8 publication Critical patent/WO2005070924A8/en
Priority to IL177013A priority patent/IL177013A0/en
Priority to NO20063747A priority patent/NO337705B1/en
Priority to HK07106003.5A priority patent/HK1100927A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

The present invention relates to novel substituted quinoline derivatives according to the general formula (Ia) or the general formula (Ib) salts, quaternary amines, stereochemically isomeric forms, tautomeric forms and N­-oxide forms thereof, wherein R1 is hydrogen, halo, haloalkyl, cyano, hydroxy, Ar, Het, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl ; p is 1, 2, 3 or 4 ; R2 is hydrogen, hydroxy, thio, alkyloxy, alkyloxyalkyloxy, alkylthio, mono or di(alkyl)amino or a radical of formula (Ic); R3 is alkyl, Ar, Ar-alkyl, Het or Het-alkyl; R4 is hydrogen, alkyl or benzyl; R5 is hydrogen, halo, haloalkyl, hydroxy, Ar, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl ; or two vicinal R5 radicals may be taken together to form together with the phenyl ring to which they are attached a naphthyl; r is 1, 2, 3, 4 or 5 ; R6 is hydrogen, alkyl, Ar or Het R7 is hydrogen or alkyl; R8 is oxo ; or R7 and R8 taken together form the radical - CH=CH-N=; Z is CH2 or C(=O). The claimed compounds are useful for the treatment of mycobacterial diseases, particularly those diseases caused by pathogenic mycobacteria such as M. tuberculosis, M. bovis, M. avium, M. smegmatis and M. marinum. Also claimed is a pharmaceutical composition containing a compound of the present invention, the use of the claimed compounds or compositions for the manufacture of a medicament for the treatment of mycobacterial diseases and a process for preparing the claimed compounds.
PCT/EP2005/050267 2004-01-23 2005-01-21 Substituted quinolines and their use as mycobacterial inhibitors WO2005070924A1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
KR1020067013237A KR101150172B1 (en) 2004-01-23 2005-01-21 Substituted quinolines and their use as mycobacterial inhibitors
CN2005800026797A CN1910177B (en) 2004-01-23 2005-01-21 Substituted quinolines and their use as mycobacterial inhibitors
AP2006003693A AP2188A (en) 2004-01-23 2005-01-21 Substituted quinolines and their use as mycobacterial inhibitors.
EA200601363A EA011359B1 (en) 2004-01-23 2005-01-21 Substituted quinolines and their use as mycobacterial inhibitors
DE602005006101T DE602005006101T2 (en) 2004-01-23 2005-01-21 SUBSTITUTED CHINOLINES AND THEIR USE AS INHIBITORS OF MYCOBACTERIA
CA2553266A CA2553266C (en) 2004-01-23 2005-01-21 Substituted quinolines and their use as mycobacterial inhibitors
AU2005206330A AU2005206330B2 (en) 2004-01-23 2005-01-21 Substituted quinolines and their use as mycobacterial inhibitors
JP2006550174A JP4773975B2 (en) 2004-01-23 2005-01-21 Substituted quinolines and their use as mycobacterial inhibitors
BRPI0507076A BRPI0507076B8 (en) 2004-01-23 2005-01-21 substituted quinolines, their preparation process, pharmaceutical composition comprising them and their use as mycobacterial inhibitors
US10/596,386 US7338949B2 (en) 2004-01-23 2005-01-21 Mycobacterial inhibitors
NZ547277A NZ547277A (en) 2004-01-23 2005-01-21 Substituted quinolines and their use as mycobacterial inhibitors
EP05701586A EP1711492B1 (en) 2004-01-23 2005-01-21 Substituted quinolines and their use as mycobacterial inhibitors
IL177013A IL177013A0 (en) 2004-01-23 2006-07-20 Substituted quinolines and their use as mycobacterial inhibitors
NO20063747A NO337705B1 (en) 2004-01-23 2006-08-22 Substituted quinolines and their use as mycobacterial inhibitors
HK07106003.5A HK1100927A1 (en) 2004-01-23 2007-06-06 Substituted quinolines and their use as mycobacterial inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53876804P 2004-01-23 2004-01-23
US60/538,768 2004-01-23

Publications (2)

Publication Number Publication Date
WO2005070924A1 WO2005070924A1 (en) 2005-08-04
WO2005070924A8 true WO2005070924A8 (en) 2006-05-11

Family

ID=34807224

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/050267 WO2005070924A1 (en) 2004-01-23 2005-01-21 Substituted quinolines and their use as mycobacterial inhibitors

Country Status (20)

Country Link
US (1) US7338949B2 (en)
EP (1) EP1711492B1 (en)
JP (1) JP4773975B2 (en)
KR (1) KR101150172B1 (en)
CN (1) CN1910177B (en)
AP (1) AP2188A (en)
AT (1) ATE392423T1 (en)
AU (1) AU2005206330B2 (en)
BR (1) BRPI0507076B8 (en)
CA (1) CA2553266C (en)
DE (1) DE602005006101T2 (en)
EA (1) EA011359B1 (en)
ES (1) ES2306082T3 (en)
HK (1) HK1100927A1 (en)
IL (1) IL177013A0 (en)
NO (1) NO337705B1 (en)
NZ (1) NZ547277A (en)
UA (1) UA85570C2 (en)
WO (1) WO2005070924A1 (en)
ZA (1) ZA200606070B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005210036B2 (en) * 2004-01-29 2010-12-23 Janssen Pharmaceutica N.V. Quinoline derivatives for use as mycobacterial inhibitors
EE05697B1 (en) * 2005-06-08 2014-02-17 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents
JO2837B1 (en) * 2005-08-03 2014-09-15 جانسن فارمسيتكا ان في Quinoline Derivatives as Antibacterial Agents
JO2855B1 (en) 2005-08-03 2015-03-15 شركة جانسين فارماسوتيكا ان. في Qunioline Derivatives as Antibacterial Agents
EP1917245A1 (en) 2005-08-21 2008-05-07 Abbott GmbH & Co. KG Heterocyclic compounds and their use as binding partners for 5-ht5 receptors
JO2970B1 (en) 2006-12-06 2016-03-15 جانسين فارماسوتيكا ان. في Antibacterial Quinoline Derivatives
JO3271B1 (en) 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv Antibacterial Quinoline Derivatives
JO2684B1 (en) 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان في Antibacterial Quinoline Derivatives
JO2685B1 (en) 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان في Antibacterial Quinoline Derivatives
CA2711912A1 (en) * 2008-01-14 2009-07-23 Jyoti Chattopadhyaya Quinoline, naphthalene and conformationally constrained quinoline or naphthalene derivates as anti-mycobacterial agents
CA2869718C (en) * 2012-04-27 2021-05-11 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
US9617244B2 (en) * 2012-04-27 2017-04-11 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
CA2984202A1 (en) * 2015-04-29 2016-11-03 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Anti-phytopathogenic compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018326A1 (en) * 1996-10-28 1998-05-07 Department Of The Army, U.S. Government Compounds, compositions and methods for treating antibiotic-resistant infections
TR199902923T2 (en) * 1997-06-02 2000-11-21 Janssen Pharmaceutica N.V. Yumu�ak kas h�cresi�o�almas� olarak (imidazole-5-yl)methyl-2-quinolinone trevleri inhibitor.
JP2002505689A (en) * 1997-06-19 2002-02-19 セプレイコー インコーポレイテッド Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
CA2397558A1 (en) * 2000-02-24 2001-08-30 Janssen Pharmaceutica N.V. Dosing regimen
UA76726C2 (en) * 2000-10-02 2006-09-15 Янссен Фармацевтика Н.В. Metabotropic antagonists of glutamate receptor, process for preparing thereof (variants), pharmaceutical composition and process for preparing thereof
EP1527050B1 (en) * 2002-07-25 2010-04-07 Janssen Pharmaceutica N.V. Quinoline derivatives and their use as mycobacterial inhibitors

Also Published As

Publication number Publication date
US20070082895A1 (en) 2007-04-12
NO337705B1 (en) 2016-06-06
DE602005006101T2 (en) 2009-07-02
ATE392423T1 (en) 2008-05-15
CN1910177B (en) 2010-05-05
EA200601363A1 (en) 2006-12-29
CN1910177A (en) 2007-02-07
AP2188A (en) 2010-12-14
KR20060127016A (en) 2006-12-11
AU2005206330A1 (en) 2005-08-04
BRPI0507076A (en) 2007-06-19
CA2553266C (en) 2013-03-12
UA85570C2 (en) 2009-02-10
CA2553266A1 (en) 2005-08-04
NO20063747L (en) 2006-08-22
EP1711492A1 (en) 2006-10-18
EP1711492B1 (en) 2008-04-16
KR101150172B1 (en) 2012-05-25
JP4773975B2 (en) 2011-09-14
US7338949B2 (en) 2008-03-04
ZA200606070B (en) 2007-12-27
JP2007518775A (en) 2007-07-12
BRPI0507076B1 (en) 2019-06-25
EA011359B1 (en) 2009-02-27
AP2006003693A0 (en) 2006-08-31
NZ547277A (en) 2009-08-28
IL177013A0 (en) 2006-12-10
HK1100927A1 (en) 2007-10-05
DE602005006101D1 (en) 2008-05-29
BRPI0507076B8 (en) 2021-05-25
AU2005206330B2 (en) 2010-09-16
WO2005070924A1 (en) 2005-08-04
ES2306082T3 (en) 2008-11-01

Similar Documents

Publication Publication Date Title
WO2005070924A8 (en) Substituted quinolines and their use as mycobacterial inhibitors
TW200744594A (en) Quinoline derivatives as antibacterial agents
ME00131B (en) Quinoline derivatives and their use as mycobacterial inhibitors
UA95915C2 (en) Quinoline derivatives as antibacterial agents
HK1122804A1 (en) Antibacterial quinoline derivatives
CY1113535T1 (en) KINOLIN PRODUCTS AS ANTIBACTERIAL AGENTS
JO3322B1 (en) Quinoline derivatives as antibacterial agents
MY153291A (en) Quinoline derivatives as antibacterial agents
MY151030A (en) Quinoline derivatives as antibacterial agents
EA200500802A1 (en) TREATMENT OF LATENT TUBERCULOSIS
TH80291B (en) Latent Tuberculosis Treatment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 31/2005 UNDER (72, 75) THE ADDRESS SHOULD READ "C/O JOHNSON& JOHNSON PHARMACEUTICAL, RESEARCH AND DEVELOPMENT, A DIVISION OF JANSSEN-CILAG, CAMPUS DE MAIGREMONT, BP 615, F-27106 VAL DE REUIL CEDEX (FR)."

WWE Wipo information: entry into national phase

Ref document number: 1200600769

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 547277

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2005206330

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007082895

Country of ref document: US

Ref document number: 10596386

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2005206330

Country of ref document: AU

Date of ref document: 20050121

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005206330

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 12006501242

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 1020067013237

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2553266

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 200580002679.7

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 177013

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 200606070

Country of ref document: ZA

Ref document number: PA/a/2006/008313

Country of ref document: MX

Ref document number: 2006550174

Country of ref document: JP

Ref document number: AP/P/2006/003693

Country of ref document: AP

Ref document number: 4215/DELNP/2006

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2005701586

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200601363

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2005701586

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067013237

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 10596386

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0507076

Country of ref document: BR

WWG Wipo information: grant in national office

Ref document number: 2005701586

Country of ref document: EP